Repatriation of a patient with COVID-19 contributed to the importation of an emerging carbapenemase producer

Objectives: Patients hospitalised abroad can become colonised with multidrug-resistant bacteria and im-port them to their home countries. In this study, we characterised an OXA-484 carbapenemase-producing Escherichia coli strain from a Swiss patient infected by SARS-CoV-2 and repatriated from India. Methods: At admission to Switzerland (April 2021), the patient undertook a nasopharyngeal swab to search for SARS-CoV-2 and a rectal swab to detect multidrug-resistant bacteria. Both SARS-CoV-2 and E. coli isolates were whole-genome sequenced and analysed for phylogenetic relatedness. Results: The patient was infected with the SARS-CoV-2 B.1.617.2 lineage (VOC Delta), a lineage that began to be reported across Switzerland at that time. He was also colonised with a sequence type 410 (ST410) E. coli strain (L3452210II) producing OXA-484, a single amino acid variant of OXA-181. The bla(OXA-484) gene was carried by a 51.5 kb IncX3 plasmid identical to those described in bla(OXA-181)-harbouring ST410 E. coli strains. Core genome analysis showed that L3452210II was identical (Delta SNV <= 23) to two ST410 OXA-484 producers recently reported in Qatar and Germany, but differed from other ST410 OXA-181 producers reported worldwide. Conclusion: The patient was infected by an emerging SARS-CoV-2 variant and also imported an E. coli producing OXA-484, an OXA-48-like carbapenemase not yet reported in Switzerland. The genetic back-ground of L3452210II indicated that bla(OXA-484) shared the same plasmid as bla(OXA-181), but its bacterial host differed from most of the pandemic OXA-181-producing ST410 strains reported previously. This case description underlines that the COVID-19 crisis can contribute to the worldwide spread of emerging car-bapenemase producers. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.

Automated summary

This study characterized an OXA-484 carbapenemase-producing Escherichia coli strain from a Swiss patient infected by SARS-CoV-2 and repatriated from India. The patient was found to be infected with the SARS-CoV-2 B.1.617.2 lineage and colonized with a sequence type 410 E. coli strain producing OXA-484, a carbapenemase not yet reported in Switzerland.